PET imaging quantifying 68Ga-PSMA-11 uptake in metastatic colorectal cancer
from The Journal of Nuclear Medicine
At diagnosis 22% of colorectal cancer patients have metastases and 50% later develop metastasis. Peptide receptor radionuclide therapy with lutetium-177 (177Lu)-PSMA-617 is employed to treat metastatic prostate cancer.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063